European Penny Stocks To Watch In March 2025

In This Article:

As the pan-European STOXX Europe 600 Index continues its upward trajectory, marking its longest streak of weekly gains since August 2012, investors are cautiously optimistic despite mixed economic signals from major economies like Germany and France. For those willing to explore beyond the established market leaders, penny stocks—often representing smaller or newer companies—remain a relevant investment area. While historically seen as speculative, these stocks can offer unique growth opportunities when backed by strong financials and resilience against broader market uncertainties.

Top 10 Penny Stocks In Europe

Name

Share Price

Market Cap

Financial Health Rating

Angler Gaming (NGM:ANGL)

SEK3.92

SEK293.94M

★★★★★★

Transferator (NGM:TRAN A)

SEK2.29

SEK221.95M

★★★★★★

Deceuninck (ENXTBR:DECB)

€2.135

€295.47M

★★★★★★

Hifab Group (OM:HIFA B)

SEK3.84

SEK233.62M

★★★★★★

Netgem (ENXTPA:ALNTG)

€0.978

€32.75M

★★★★★★

High (ENXTPA:HCO)

€2.69

€52.84M

★★★★★★

I.M.D. International Medical Devices (BIT:IMD)

€1.43

€24.77M

★★★★★☆

Bredband2 i Skandinavien (OM:BRE2)

SEK2.065

SEK1.98B

★★★★☆☆

Arcure (ENXTPA:ALCUR)

€4.81

€27.81M

★★★★☆☆

IMS (WSE:IMS)

PLN3.65

PLN123.71M

★★★★☆☆

Click here to see the full list of 432 stocks from our European Penny Stocks screener.

Let's dive into some prime choices out of the screener.

ForFarmers

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: ForFarmers N.V. operates as a provider of feed solutions for both conventional and organic livestock farming across several countries including the Netherlands, the UK, Germany, Poland, and Belgium, with a market cap of €376.89 million.

Operations: The company generates revenue of €2.75 billion from its food processing segment.

Market Cap: €376.89M

ForFarmers N.V. has recently turned profitable, reporting a net income of €31.4 million for 2024 compared to a loss the previous year. Despite an 8.5% annual decline in earnings over five years, its financial health is supported by short-term assets exceeding liabilities and satisfactory debt coverage with operating cash flow at 65.3%. The stock trades significantly below its estimated fair value, offering potential upside if market conditions improve. However, challenges include an unstable dividend track record and a relatively inexperienced management team with an average tenure of 1.5 years, which may impact strategic execution moving forward.

ENXTAM:FFARM Revenue & Expenses Breakdown as at Mar 2025
ENXTAM:FFARM Revenue & Expenses Breakdown as at Mar 2025

Miliboo Société anonyme

Simply Wall St Financial Health Rating: ★★★★★★